glp-1 and addiction Weight-Loss Drugs Could Address a Range of Addictions Researchers from @pennstate are pioneering

In this study, we established an obesity (induced by HFD)-related AF mice model, which showed increased AF vulnerability and exhibited apparent atrial structural remodeling (Figures 1, 2)

**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A

See the end of the Medication Guide for a complete list of ingredients in Qsymia

I felt helpless

2025 (PMC12313605) BPC-157 systematic review Pickart L et al